synthetic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Neuromarketing consultant Zack Lynch argues that neurotechnologies will have a more immediate effect on society than gene therapy and will face less resistance as a pathway of radical human enhancement. He also argues that the concept of "enablement" needs to be added to the debate over "therapy" versus "enhancement". The prospect of human enhancement has sparked public controversy. The main ethical question in the debate about human enhancement involves which legal restrictions, if any, should exist. Dale Carrico wrote that "human enhancement" is a loaded term which has eugenic overtones because it may imply the improvement of human hereditary traits to attain a universally accepted norm of biological fitness (at the possible expense of human biodiversity and neurodiversity), and therefore can evoke negative reactions far beyond the specific meaning of the term. Michael Selgelid terms this as a phase of "neugenics" suggesting that gene enhancements occurring now have already revived the idea of eugenics in our society. Practices of prenatal diagnosis, selective abortion and in-vitro fertilization aims to improve human life allowing for parents to decide via genetic information if they want to continue or terminate the pregnancy. A criticism of human enhancement is that it will create unfair physical or mental advantages, or unequal access to such enhancements, can and will further the gulf between the "haves" and "have-nots".
=== School mergers and consolidation (2009–2020) === In 2009, the Prince George's County Public Schools Board voted to merge eight under-enrolled schools and bolster its magnet program offerings. This decision was informed by community consultations, public hearings, and over 2,500 survey responses. Key aspects of the 2009 consolidation:
Chilblains, also known as pernio, is a medical condition in which damage occurs to capillary beds in the skin, most often in the hands or feet, when blood perfuses into the nearby tissue, resulting in redness, itching, inflammation, and possibly blisters. It occurs most frequently when predisposed individuals, predominantly women, are exposed to cold and humidity. Ulcerated chilblains are referred to as kibes. Temperature-related chilblains can be prevented by keeping the feet and hands warm in cold weather and avoiding exposing these areas to extreme temperature changes. Once the diagnosis of chilblains is made, first-line treatment includes avoiding cold, damp environments and wearing gloves and warm socks. Chilblains can be idiopathic (spontaneous and unrelated to another disease), but similar symptoms may also be a manifestation of another serious medical condition that must be investigated. Related medical conditions include Raynaud syndrome, erythromelalgia, frostbite, and trench foot, as well as connective tissue diseases such as lupus or vasculitis. In infants affected by Aicardi–Goutières syndrome (a rare inherited condition which affects the nervous system), chilblain-like symptoms occur together with severe neurologic disturbances and unexplained fevers.
Sources: en.wikipedia.org
The earliest published work on growing terrestrial plants without soil was the 1627 book Sylva Sylvarum or 'A Natural History' by Francis Bacon, printed a year after his death. As a result of his work, water culture became a popular research technique. In 1699, John Woodward published his water culture experiments with spearmint. He found that plants in less-pure water sources grew better than plants in distilled water. By 1842, a list of nine elements believed to be essential for plant growth had been compiled, and the discoveries of German botanists Julius von Sachs and Wilhelm Knop, in the years 1859–1875, resulted in a development of the technique of soilless cultivation. To quote von Sachs directly: "In the year 1860, I published the results of experiments which demonstrated that land plants are capable of absorbing their nutritive matters out of watery solutions, without the aid of soil, and that it is possible in this way not only to maintain plants alive and growing for a long time, as had long been known, but also to bring about a vigorous increase of their organic substance, and even the production of seed capable of germination." Growth of terrestrial plants without soil in mineral nutrient solutions was later called "solution culture" in reference to "soil culture". It quickly became a standard research and teaching technique in the 19th and 20th centuries and is still widely used in plant nutrition science.
== Later years == Lore Rogers and his wife, Beatrice, returned to Patten, Maine, following World War II. He opened a dairy business, which proved highly successful. In 1953, Rogers' wife of 47 years died. At about the same time, he seized upon the idea of building a museum to honor and preserve the history of lumbering, the profession of his family and townsfolk and the force behind the town's development. Longtime resident, Patten Academy graduate and game warden Caleb W. Scribner joined him as co-founder, and soon they were engaged in collecting artifacts and photographs and in building displays and models to depict historic lumbering operations. Lore Rogers married Katherine Keiper Sherman, a longtime acquaintance and the widow of a colleague. She aided in the development of the museum and helped welcome the guests who stopped by to tour the museum and to visit Lore. Professional interests continued, and Lore Rogers was elected an honorary member of the American Society of Microbiologists. He was formally recognized by the American Dairy Science Association for his many contributions to the field. The State of Maine acknowledged Rogers' contributions to the humanities, and the Maine Legislature offered a citation. The American Society for Microbiology published a long tribute in their News to celebrate his 100th birthday. Rogers' mind remained alert, though he was increasingly impatient with physical frailty and at age 99 complained,
Yeast is used in winemaking, where it converts the sugars present (glucose and fructose) in grape juice (must) into ethanol. Yeast is normally already present on grape skins. Fermentation can be done with this endogenous "wild yeast", but this procedure gives unpredictable results, which depend upon the exact types of yeast species present. For this reason, a pure yeast culture is usually added to the must; this yeast quickly dominates the fermentation. The wild yeasts are repressed, which ensures a reliable and predictable fermentation. Most added wine yeasts are strains of S. cerevisiae, though not all strains of the species are suitable. Different S. cerevisiae yeast strains have differing physiological and fermentative properties, therefore the actual strain of yeast selected can have a direct impact on the finished wine. Significant research has been undertaken into the development of novel wine yeast strains that produce atypical flavour profiles or increased complexity in wines. The growth of some yeasts, such as Zygosaccharomyces and Brettanomyces, in wine can result in wine faults and subsequent spoilage. Brettanomyces produces an array of metabolites when growing in wine, some of which are volatile phenolic compounds. Together, these compounds are often referred to as "Brettanomyces character", and are often described as "antiseptic" or "barnyard" type aromas. Brettanomyces is a significant contributor to wine faults within the wine industry. Researchers from the University of British Columbia, Canada, have found a new strain of yeast that has reduced amines.
== Health risks == Acrolein is toxic and is a strong irritant for the skin, eyes, and nasal passages. The main metabolic pathway for acrolein is the alkylation of glutathione. The WHO suggests a "tolerable oral acrolein intake" of 7.5 μg per day per kg of body weight. Although acrolein occurs in French fries (and other fried foods), the levels are only a few μg per kg, meaning that one would have to consume more than their body weight in fries every day to surpass the limit set by the WHO. In response to occupational exposures to acrolein, the US Occupational Safety and Health Administration has set a permissible exposure limit at 0.1 ppm (0.25 mg/m3) at an eight-hour time-weighted average. Acrolein acts in an immunosuppressive manner and may promote regulatory cells, thereby preventing the generation of allergies on the one hand, but also increasing the risk of cancer. Acrolein was identified as one of the chemicals involved in the 2019 Kim Kim River toxic pollution incident.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.